Free Alerts   Login
Health Care › Laboratory Analytical Instruments

A Stock Price Correlated With Agilent Technologies Financials

A Stock Price vs. Quarterly
A
Income Statement
Cash Flow
Balance Sheet

A Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

A Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

A Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Blackrock.
27,257,939 sh
-757,429 sh
-3%
$3,789,671
$656,994
Vanguard Group
25,279,117 sh
206,865 sh
1%
$3,514,556
$710,977
Massachusetts Financial Services /Ma/
13,246,489 sh
2,170,219 sh
20%
$1,841,658
$603,108
State Street
12,634,456 sh
5,288 sh
0%
$1,759,527
$347,333
T. Rowe Price Investment Management.
10,154,406 sh
877,865 sh
9%
$1,412
$129
Wellington Management Group Llp
9,883,132 sh
-372,394 sh
-4%
$1,374,052
$227,279
Price T Rowe Associates /Md/
7,499,128 sh
113,313 sh
2%
$1,042
$216
Geode Capital Management
6,604,203 sh
107,407 sh
2%
$915,798
$190,877
Morgan Stanley
4,501,663 sh
209,463 sh
5%
$625,868
$145,915
Deutsche Bank Ag\
4,190,623 sh
437,454 sh
12%
$582,620
$162,941
Northernrp
3,997,643 sh
-99,670 sh
-2%
$555,793
$97,632
State Farm Mutual Automobile Insurance
3,825,278 sh
-125,531 sh
-3%
$531,828
$90,049
Norges Bank
3,667,584 sh
3,667,584 sh
NEW
$509,904
$509,904
Cantillon Capital Management
3,641,879 sh
-89,581 sh
-2%
$506,330
$89,078
JPMorgan Chase
3,179,473 sh
149,987 sh
5%
$442,041
$103,283
Legal & General Group Plc
3,111,575 sh
351,090 sh
13%
$432,602
$123,924
Principal Financial Group
2,889,237 sh
-559,191 sh
-16%
$401,691
$16,088
Van Eck Associates
2,749,857 sh
153,630 sh
6%
$382
$92
Nordea Investment Management Ab
2,666,416 sh
1,867,377 sh
234%
$370,552
$280,700
Bank Of New York Mellon
2,650,777 sh
-26,500 sh
-1%
$368,537
$69,164
COMPANY PROFILE
OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Overview. Agilent Technologies, Inc. ("we," "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.

Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, these dates refer to our fiscal year and fiscal quarters.

New Segment Structure. In the first quarter of fiscal year 2022, we announced a change in organizational structure designed to enable our growth strategies and strengthen our focus on customers. Our chemistries and supplies business and our remarketed instruments business moved from our Agilent CrossLab business segment to our life sciences and applied markets business segment. Service revenue and cost of sales related to the previous acquisition of BioTek moved from our life sciences and applied markets business segment to our Agilent CrossLab business segment. Following this reorganization, we continue to have three business segments (life sciences and applied markets, diagnostics and genomics and Agilent CrossLab), each of which continues to comprise a reportable segment. We began reporting under this new structure with the Quarterly Report on Form 10-Q for the period ended January 31, 2022. Historical financial segment information has been recast to conform to this new presentation in our financial statements and accompanying notes. There was no change to our diagnostics and genomics business segment.

Basis of Presentation . We have prepared the accompanying financial data for the three and six months ended April 30, 2022 and 2021 pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. have been condensed or omitted pursuant to such rules and regulations. The October 31, 2021 condensed balance sheet data was derived from audited financial statements but does not include all the disclosures required in audited financial statements by U.S. GAAP. The accompanying financial data and information should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended October 31, 2021.

In the opinion of management, the accompanying condensed consolidated financial statements contain all normal and recurring adjustments necessary for a fair statement of our condensed consolidated balance sheet as of April 30, 2022 and October 31, 2021, condensed consolidated statement of comprehensive income (loss) for the three and six months ended April 30, 2022 and 2021, condensed consolidated statement of operations for the three and six months ended April 30, 2022 and 2021, condensed consolidated statement of cash flows for the six months ended April 30, 2022 and 2021 and condensed consolidated statement of equity for the three and six months ended April 30, 2022 and 2021.

Use of Estimates. The preparation of condensed consolidated financial statements in accordance with GAAP in the U.S. requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue

Free historical financial statements for Agilent Technologies Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 37 quarters since 2015. Compare with A stock chart to see long term trends.

Data imported from Agilent Technologies Inc SEC filings. Check original filings before making any investment decision.